12th Jan 2016 08:39
LONDON (Alliance News) - Pharmaceutical services company Venn Life Sciences Holdings PLC on Tuesday said it has signed contracts worth a total of EUR3.4 million with an unnamed US-based biotechnology client.
The contracts are extension of an existing programme already in place with the client, Venn said. The work will start immediately and will run to the end of 2017 in sites in the US and Europe.
"It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business," said Tony Richardson, Venn's chief executive.
Venn shares were up 3.5% to 25.10 pence early Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Venn Life Sciences